Actualités et vidéos - CV SCIENCES INC. CVSI

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended March 31, 2022. First Quarter 2022 and Recent Financial and Operating Highlights Revenue of $4.4 million for first quarter of 2022, compared to $4.8 million for the first quarter of 2021; Gross margin of 26.0% for...

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the first quarter ended March 31, 2022, before the stock market opens on Monday, May 16, 2022. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time)...

SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the year ended December 31, 2021. Fiscal 2021 and Recent Financial and Operating Highlights Revenue of $20.0 million for fiscal year 2021, compared to $24.4 million for 2020; Gross margin of 43.0% for fiscal year 2021, compared to...

SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2021, after the stock market closes on Thursday, March 31, 2022. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time...

SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the addition of +PlusCBD Relief Softgels to its Wellness line of CBD products, joining our highly successful +PlusCBD Sleep & Calm Gummies. +PlusCBD Relief Softgels deliver seven times more CBDA and CBD than the original +PlusCBD Raw formula and feature...

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the addition of +PlusCBD Relief Softgels to its Wellness line of CBD products, joining our highly successful +PlusCBD Sleep & Calm Gummies. +PlusCBD Relief Softgels deliver seven times more CBDA and CBD than the original +PlusCBD raw formula and feature...

SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (“CBD”) products, today announced the launch of +PlusCBD™ Pain Relief topicals: four unique Over-the-Counter (“OTC”) products formulated to pinpoint sources of minor pain and aches using active ingredients including warming camphor and cooling menthol along with premium...

SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it has appointed Haskell & White LLP ("H&W") as the Company's new independent registered public accounting firm. "Following a thorough selection process, the Company's Audit Committee has concluded that H&W is best positioned to meet the evolving needs of...

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it has entered into a securities purchase agreement with an institutional investor, providing for the sale and issuance of convertible notes due 2022 in the aggregate original principal amount of $1.06 million. Upon our filing with the Securities and...

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended September 30, 2021. Third Quarter 2021 and Recent Financial and Operating Highlights Revenue of $5.1 million for third quarter of 2021, compared to $5.6 million for the third quarter of 2020; Gross margin of 46.2%...

SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the third quarter ended September 30, 2021, before the stock market opens on Monday, November 15, 2021. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m....

SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, applauds the California Legislature of its passage of AB 45 , which yesterday was signed into law by Governor Gavin Newson. This new law will explicitly permit the retail sale of products containing hemp-derived extracts and cannabinoids, such as CBD. “As a California-based...

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended June 30, 2021. Second Quarter 2021 and Recent Financial and Operating Highlights Revenue of $5.1 million for second quarter of 2021, compared to $5.4 million for the second quarter of 2020; Gross margin of 44.7% for...

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the second quarter ended June 30, 2021, after the stock market closes on Thursday, August 12 , 2021. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern...

SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, announced today that it received NutraIngredients-USA ’s 2021 Product of the Year: Immune Support Award for its CV™ Defense product. Focusing on true innovation, long-term market success and cutting-edge research, the NutraIngredients-USA Awards honor the best and...

SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced progress toward its goal of developing and commercializing a CBD-based pharmaceutical to treat nicotine addiction in smokeless tobacco users. The Company, in collaboration with researchers from the University of California, San Diego (“UC San Diego”), published a...

SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the quarter ended March 31, 2021. First Quarter 2021 and Recent Operating Highlights Revenue of $4.8 million for first quarter of 2021, compared to $8.3 million for the first quarter of 2020; Gross margin of 48.7% for first quarter of...

SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced the launch of PlusCBD™ Calm and Sleep: two flavorful gummies that support healthy stress responses and sleep cycles for people getting back to their normal routines. Each PlusCBD™ Calm gummy contains 10mg of CBD derived from sustainable hemp and two...

SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the first quarter ended March 31, 2021, after the stock market closes on Thursday, May 13, 2021. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time)...

SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp derived cannabidiol (CBD) products, today announced an ongoing partnership with Alkemist Labs, an established leader in botanical plant testing, to collaborate with the National Institute of Standards and Technology (“NIST”) on efforts to help cannabis testing labs demonstrate and improve measurement capabilities and...